Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

2F-QMPSBAlso known as SGT-13

A synthetic cannabinoid with a sulfamoyl benzoate core, designed outside the families covered by generic clauses.

Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₂₂H₂₀F₂N₂O₄S

CAS 2707165-48-6

Family
Synthetic CB receptor agonistNew psychoactive substance
Molar mass
446.50 g/mol

Updated on

In plain terms

2F-QMPSB is a synthetic cannabinoid made in a laboratory, spotted in 2018 in herbal products seized in Europe. Its structure is very different from that of the best-known synthetic cannabinoids. No measurement of its action on the receptors was found, and it is not cited in the French list of narcotics.

Receptors and activity

Target network

CB1AgonistClassified as a cannabinoid receptor agonist (SCRA); no published affinity or efficacy value found
  • Activates

The lower the cited value, the closer the target sits to 2F-QMPSB: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of 2F-QMPSB.

Brain, side view
Body, front view
Blood

CB1CB1 found in 7 regions of the body

  1. Basal gangliadenseMost dense in basal ganglia outflow nuclei1
  2. CerebellumdenseVery dense in the cerebellum1
  3. HippocampusdenseVery high concentrations in the hippocampus2
  4. AmygdaladenseHigh concentrations in the amygdala2
  5. CortexpresentPresent throughout the neocortex2
  6. Adipose tissuepresentExpressed in adipose tissue3
  7. GutpresentColonic epithelium, smooth muscle and plexus4

Cited values

  1. CB1Agonistno measured value cited

    Classified as a cannabinoid receptor agonist (SCRA); no published affinity or efficacy value found

  2. CB2Agonistno measured value cited

    Classified as a cannabinoid receptor agonist (SCRA); no published value found

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

2F-QMPSB (SGT-13) belongs to a little-studied group of synthetic cannabinoids with a sulfamoyl benzoate, sulfamoyl benzamide or N-benzoylpiperidine core (Brandt et al. 2021). Brandt et al. recall that the company Stargate International investigated and developed six of these compounds between 2011 and early 2014 with a view to marketing, and that the quinolin-8-yl head group of the series paved the way for PB-22 (SGT-21) and BB-22 (SGT-32). A parcel seized in February 2018 at Malpensa airport supplied the three plant samples in which Tsochatzis et al. (2021) identified 2F-QMPSB, with its acid precursor 2F-MPSBA, by gas chromatography-mass spectrometry, nuclear magnetic resonance (1H, 13C, 19F, 15N) and high-resolution tandem mass spectrometry; it was notified to the EMCDDA on 9 January 2019. Richter et al. (2023) described its in vitro metabolism: ester hydrolysis, catalysed mainly by the human carboxylesterases hCES1 and also non-enzymatic, gives a carboxylic acid detectable only in negative ionisation mode. No measurement of affinity or efficacy at the cannabinoid receptors was found, and no human data.

History

Source
A wholly synthetic compound, with no natural occurrence. It was identified in three samples of herbal material from a postal parcel seized in February 2018 at Malpensa airport (Italy), sent from Spain and declared as an air freshener or herbal incense, together with several other synthetic cannabinoids (Tsochatzis et al. 2021). It was notified to the EMCDDA on 9 January 2019 (Tsochatzis et al. 2021). None of this has anything to do with hemp or with cannabidiol products.

Origin

Laboratory synthesis

Entirely chemical origin: the molecule is entirely synthetic and belongs to the family of the quinolin-8-yl sulfamoyl benzoates; it differs from QMPSB, the lead compound of the series, by the difluorination of the piperidine ring (Brandt et al. 2021).

Classification

Family, origin and source verification

Family

Synthetic CB receptor agonist › New psychoactive substance

Class

sulfamoyl benzoate (quinolin-8-yl ester)

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

2F-QMPSB (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

Identifiers

Names

Common name
2F-QMPSB (SGT-13)
IUPAC name
quinolin-8-yl 3-(4,4-difluoropiperidin-1-yl)sulfonyl-4-methylbenzoate
Other names
SGT-13 · QMDFPSB · 2-fluoro QMPSB

Identifiers

Formula
C₂₂H₂₀F₂N₂O₄S
CAS
2707165-48-6
InChIKey
JOSWCKYCXJMLNM-UHFFFAOYSA-N
SMILES
FC1(F)CCN(CC1)S(=O)(=O)c2cc(ccc2C)C(=O)Oc4cccc3cccnc34

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.